PARD (Poniard Pharmaceuticals) EBIT: $-15.53 Mil (TTM As of Sep. 2011)


What is Poniard Pharmaceuticals EBIT?

Poniard Pharmaceuticals PARD EBIT is $-15.53 Mil as of Sep. 2011.

Poniard Pharmaceuticals's earnings before interest and taxes (EBIT) for the three months ended in Sep. 2011 was $-3.75 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Sep. 2011 was $-15.53 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Poniard Pharmaceuticals's annualized ROC % for the quarter that ended in Sep. 2011 was -265.84%. Poniard Pharmaceuticals's annualized ROC (Joel Greenblatt) % for the quarter that ended in Sep. 2011 was -69,730.23%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield.

Poniard Pharmaceuticals  (OTCPK:PARD) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Poniard Pharmaceuticals's annualized ROC % for the quarter that ended in Sep. 2011 is calculated as:

ROC % (Q: Sep. 2011 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Jun. 2011 ) + Invested Capital (Q: Sep. 2011 ))/ count )
=-14.992 * ( 1 - % )/( (5.795 + 5.484)/ 2 )
=-14.992/5.6395
=-265.84 %

where

Invested Capital(Q: Jun. 2011 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=9.989 - 2.087 - ( 3.692 - max(0, 2.087 - 4.194+3.692))
=5.795

Invested Capital(Q: Sep. 2011 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=7.736 - 2.979 - ( 1.984 - max(0, 2.979 - 2.252+1.984))
=5.484

Note: The Operating Income data used here is four times the quarterly (Sep. 2011) data.

2. Joel Greenblatt's definition of Return on Capital:

Poniard Pharmaceuticals's annualized ROC (Joel Greenblatt) % for the quarter that ended in Sep. 2011 is calculated as:

ROC (Joel Greenblatt) %(Q: Sep. 2011 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Jun. 2011  Q: Sep. 2011
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=-14.992/( ( (0.025 + max(-1.585, 0)) + (0.018 + max(-2.711, 0)) )/ 2 )
=-14.992/( ( 0.025 + 0.018 )/ 2 )
=-14.992/0.0215
=-69,730.23 %

where Working Capital is:

Working Capital(Q: Jun. 2011 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0 + 0 + 0.502) - (2.087 + 0 + 0)
=-1.585

Working Capital(Q: Sep. 2011 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0 + 0 + 0.268) - (2.979 + 0 + 0)
=-2.711

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Sep. 2011) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Poniard Pharmaceuticals's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %=EBIT (TTM)/Enterprise Value (Q: Sep. 2011 )
=-15.533/0.000
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Poniard Pharmaceuticals EBIT Related Terms

Poniard Pharmaceuticals EBIT Historical Data

* Premium members only.

The historical data trend for Poniard Pharmaceuticals's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Poniard Pharmaceuticals EBIT Chart

Poniard Pharmaceuticals Annual Data
Trend Dec01 Dec02 Dec03 Dec04 Dec05 Dec06 Dec07 Dec08 Dec09 Dec10
EBIT
Get a 7-Day Free Trial Premium Member Only Premium Member Only -21.23 -35.35 -49.16 -40.44 -26.33

Poniard Pharmaceuticals Quarterly Data
Dec06 Mar07 Jun07 Sep07 Dec07 Mar08 Jun08 Sep08 Dec08 Mar09 Jun09 Sep09 Dec09 Mar10 Jun10 Sep10 Dec10 Mar11 Jun11 Sep11
EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -5.95 -4.72 -3.23 -3.84 -3.75

PARD vs OBMP, NSPX, ATRX: EBIT Comparison

For the Biotechnology subindustry, Poniard Pharmaceuticals's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Poniard Pharmaceuticals EV-to-EBIT vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Poniard Pharmaceuticals's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Poniard Pharmaceuticals's EV-to-EBIT falls into.


Poniard Pharmaceuticals EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Sep. 2011 adds up the quarterly data reported by the company within the most recent 12 months, which was $-15.53 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBIT →
What does a EBIT of $-15.53 Mil mean?
Poniard Pharmaceuticals (PARD) has a EBIT of $-15.53 Mil as of Sep. 2011. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Poniard Pharmaceuticals.
Is Poniard Pharmaceuticals' EBIT too high?
Poniard Pharmaceuticals' current EBIT is $-15.53 Mil.
How does Poniard Pharmaceuticals' EBIT compare to OBMP and NSPX?
Poniard Pharmaceuticals' EBIT of $-15.53 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT for a Biotechnology company?
A good EBIT depends on the Biotechnology industry context. However, EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT mean?
A high EBIT can signal that a stock is expensive relative to its fundamentals. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Poniard Pharmaceuticals. Poniard Pharmaceuticals's current EBIT is $-15.53 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Poniard Pharmaceuticals stock overvalued right now?
Poniard Pharmaceuticals (PARD) has a current EBIT of $-15.53 Mil. The current EBIT is $-15.53 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT calculated?
EBIT is calculated from a company's financial statements. For Poniard Pharmaceuticals (PARD), the current EBIT is $-15.53 Mil as of Sep. 2011. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Poniard Pharmaceuticals Business Description

Address 300 Elliott Avenue West, Suite 530, Seattle, CA, USA, 98119
Poniard Pharmaceuticals Inc is a biopharmaceutical company engaged in the development and commercialization of cancer therapeutics. Its product candidate is picoplatin, a new generation platinum-based cancer therapy.